Similarly, patients positive for other lymphoid markers, such as CD3 and CD7, or for at least two of the following—CD22, CD10, and CD79, but who were negative for CD19, did well on an the ALL-like regimen. The gene discussed is CD7; the disease is acute lymphoblastic leukemia.